Buy Sermorelin Research Peptide

What is Sermorelin?

Sermorelin (GRF 1-29) is a synthetic peptide matching the first 29 building blocks of GHRH, the hormone that prompts growth-hormone release. It is the shortest piece that still fully activates the GHRH receptor, and is used in research as a reference tool for growth-hormone release.

• The first 29 amino acids of GHRH, the shortest piece that fully activates its receptor
• Activates the pituitary GHRH receptor and is studied for growth-hormone release patterns
• Keeps the body’s normal feedback control in research models
• Studied for GHRH-receptor signaling and downstream IGF-1 effects

For research use only. Not approved for human therapeutic use.

Sermorelin (CAS 86168-78-7), also known as GRF(1-29), is a synthetic 29-amino acid peptide corresponding to the first 29 residues of endogenous human growth hormone-releasing hormone (GHRH). With the molecular formula C149H246N44O42S and a molecular weight of 3357.93 g/mol, Sermorelin acts at the GHRH receptor (GHRH-R) and is structurally and mechanistically distinct from the ghrelin receptor (GHS-R1a) agonists in the secretagogue class. Produced via solid-phase peptide synthesis.

Sermorelin is one of the most extensively studied GHRH analogues in preclinical neuroendocrinology. As a GHRH-R agonist, it engages a fundamentally different receptor system to the ghrelin-mimetic secretagogues such as GHRP-6 and Ipamorelin, making it an established comparator compound in studies examining the dual regulatory control of somatotroph function. Published in vitro research in rat anterior pituitary cell preparations has investigated Sermorelin/GRF(1-29)-mediated cyclic AMP accumulation and downstream somatotroph signalling, documenting inhibitory modulation of this response by somatostatin at the level of GHRH-R activation [1]. In vivo rodent studies have examined GH secretion patterns following Sermorelin/GRF(1-29) administration, with particular focus on ultradian pulse amplitude modulation and the interplay between GHRH and somatostatin tone within the hypothalamic-pituitary axis [2].

Sermorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Bilezikjian LM, Vale WW. Stimulation of adenosine 3’,5’-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology. 1983 Nov;113(5):1726–31. .PubMed PMID: 61949792Tannenbaum GS, Ling N. The Interrelationship of Growth Hormone (GH)-Releasing Factor and Somatostatin in Generation of the Ultradian Rhythm of GH Secretion. Endocrinology. 1984 Nov 1;115(5):1952–7.doi:10.1210/endo-115-5-1952

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →

Sermorelin (CAS 86168-78-7), also known as GRF(1-29), is a synthetic 29-amino acid peptide corresponding to the first 29 residues of endogenous human growth hormone-releasing hormone (GHRH). With the molecular formula C149H246N44O42S and a molecular weight of 3357.93 g/mol, Sermorelin acts at the GHRH receptor (GHRH-R) and is structurally and mechanistically distinct from the ghrelin receptor (GHS-R1a) agonists in the secretagogue class. Produced via solid-phase peptide synthesis.

Sermorelin is one of the most extensively studied GHRH analogues in preclinical neuroendocrinology. As a GHRH-R agonist, it engages a fundamentally different receptor system to the ghrelin-mimetic secretagogues such as GHRP-6 and Ipamorelin, making it an established comparator compound in studies examining the dual regulatory control of somatotroph function. Published in vitro research in rat anterior pituitary cell preparations has investigated Sermorelin/GRF(1-29)-mediated cyclic AMP accumulation and downstream somatotroph signalling, documenting inhibitory modulation of this response by somatostatin at the level of GHRH-R activation [1]. In vivo rodent studies have examined GH secretion patterns following Sermorelin/GRF(1-29) administration, with particular focus on ultradian pulse amplitude modulation and the interplay between GHRH and somatostatin tone within the hypothalamic-pituitary axis [2].

Sermorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Bilezikjian LM, Vale WW. Stimulation of adenosine 3’,5’-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology. 1983 Nov;113(5):1726–31. .PubMed PMID: 61949792Tannenbaum GS, Ling N. The Interrelationship of Growth Hormone (GH)-Releasing Factor and Somatostatin in Generation of the Ultradian Rhythm of GH Secretion. Endocrinology. 1984 Nov 1;115(5):1952–7.doi:10.1210/endo-115-5-1952

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number86168-78-7Molecular Weight3,357.93 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUSERM

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.

Sermorelin (CAS 86168-78-7), also known as GRF(1-29), is a synthetic 29-amino acid peptide corresponding to the first 29 residues of endogenous human growth hormone-releasing hormone (GHRH). With the molecular formula C149H246N44O42S and a molecular weight of 3357.93 g/mol, Sermorelin acts at the GHRH receptor (GHRH-R) and is structurally and mechanistically distinct from the ghrelin receptor (GHS-R1a) agonists in the secretagogue class. Produced via solid-phase peptide synthesis.

Sermorelin is one of the most extensively studied GHRH analogues in preclinical neuroendocrinology. As a GHRH-R agonist, it engages a fundamentally different receptor system to the ghrelin-mimetic secretagogues such as GHRP-6 and Ipamorelin, making it an established comparator compound in studies examining the dual regulatory control of somatotroph function. Published in vitro research in rat anterior pituitary cell preparations has investigated Sermorelin/GRF(1-29)-mediated cyclic AMP accumulation and downstream somatotroph signalling, documenting inhibitory modulation of this response by somatostatin at the level of GHRH-R activation [1]. In vivo rodent studies have examined GH secretion patterns following Sermorelin/GRF(1-29) administration, with particular focus on ultradian pulse amplitude modulation and the interplay between GHRH and somatostatin tone within the hypothalamic-pituitary axis [2].

Sermorelin is produced to research-grade standards and independently verified by third-party HPLC and MS-UPLC analysis before dispatch. Vials are vacuum sealed and stored in a temperature controlled, monitored cold storage system. Certificates of Analysis are available on request.

Sold strictly for in vitro research purposes only. Not for human consumption. Intended for use by qualified researchers in laboratory settings only.

References

1Bilezikjian LM, Vale WW. Stimulation of adenosine 3’,5’-monophosphate production by growth hormone-releasing factor and its inhibition by somatostatin in anterior pituitary cells in vitro. Endocrinology. 1983 Nov;113(5):1726–31. .PubMed PMID: 61949792Tannenbaum GS, Ling N. The Interrelationship of Growth Hormone (GH)-Releasing Factor and Somatostatin in Generation of the Ultradian Rhythm of GH Secretion. Endocrinology. 1984 Nov 1;115(5):1952–7.doi:10.1210/endo-115-5-1952

Scientific Review

Dr. Martina Rossi, PhD

Scientific Contributor and Reviewer

Reviewed for scientific accuracy, 14 June 2026

View credentials →CAS Number86168-78-7Molecular Weight3,357.93 g/molPurity≥98%Physical FormLyophilised PowderManufacturingManufactured in an ISO9001 Certified LaboratoryTestingHPLC + MS-UPLCSKUSERM

Lyophilised powder: store at -20 °C or below, away from light and moisture. Once reconstituted in an appropriate laboratory diluent (e.g. sterile water, PBS, or assay buffer), store at 2–8 °C and use within the validated period for your protocol. Do not refreeze.